# Inno Models

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inno-models

- Industry: Biotechnology
- Headquarters: Beijing, China
- Latest round: Angel (Feb 9, 2021)
- Investors on record: 2

## About

Based in Beijing, China and established in 2020, Inno Models is a CRO provider of oncology and tumor immune pharmacodynamic evaluation that focuses on tumor immune pharmacodynamics research. In February 2021, Inno Models raised an undisclosed amount in angel funding from new investors Dalton Venture and Yusen Capital.

Inno Models is dedicated to the development of next-generation pharmacodynamic in vitro and experimental animal models for tumor and tumor immunity, and has developed a variety of humanized tumor immune pharmacodynamic platforms and immune system-PDX dual-derived platforms based on a new generation of NIG heavily combined immunodeficient mice. The company has established a second-generation PBMC immune system humanization model and a second-generation PDX human tumor xenograft model, which can reconstitute a variety of immune cells including T cells, NK cells and DC cells.

## Funding rounds

- Angel, Feb 9, 2021 — Dalton Venture, Yusen Capital

## Investors

- Dalton Venture (https://capitalatlas.ai/funds/dalton-venture) — Angel
- Yusen Capital — Angel